# Vikram Joshi

> Vikram Joshi is the chief business officer of A2 Biotherapeutics and a life-sciences builder whose career has moved from materials science to point-of-care diagnostics, CRISPR business development, and logic-gated cell therapy. A Cornell and Stanford-trained materials engineer with a Wharton MBA, he co-founded Proxim Diagnostics, led it from concept toward a working product, helped build partnerships at Mammoth Biosciences, and now works at the commercial edge of A2 Bio's Tmod platform.

- **Role:** Chief Business Officer at A2 Biotherapeutics, Inc.
- **Organizations:** A2 Biotherapeutics, Inc., Mammoth Biosciences, Proxim Diagnostics, Red Ladder Media
- **Education:** B.S., Materials Science and Engineering, Cornell University, M.S., Materials Science and Engineering, Stanford University, MBA, Healthcare Management and Entrepreneurship, The Wharton School, University of Pennsylvania
- **Known for:** Won a 2007 Wharton Venture Award while pursuing his MBA., Co-founded Proxim Diagnostics and led the point-of-care diagnostics company as CEO for seven years from concept toward product realization., Named as a co-inventor on a U.S. patent for carbon-based electrodes with graphene modification, assigned to Proxim Diagnostics.

## Career timeline

- **2001** — Presented Cornell materials-science research on magnetic, organically modified aluminosilicate nano-objects with Ulrich Wiesner at the MRS Spring Meeting.
- **2007** — Won an inaugural $10,000 Wharton Venture Award, designed to let students pursue ventures instead of traditional summer internships.
- **2008** — Completed his Wharton MBA focused on healthcare management and entrepreneurship.
- **2009** — Co-founded Proxim Diagnostics, a point-of-care diagnostics company, and subsequently led it as CEO for seven years.
- **2009-2015** — Co-invented graphene-modified carbon electrode technology assigned to Proxim Diagnostics; the related U.S. patent was granted in 2015.
- **2019** — Was listed as Head of Business Development on an archived Mammoth Biosciences team page; he later became Senior Vice President, Business Development.
- **2020** — Was acknowledged for advice and discussions in Mammoth's rapid CRISPR-based detection protocol.
- **2023** — Joined A2 Biotherapeutics as Chief Business Officer.
- **2025** — A2 Bio closed an $80 million Series C and dosed the first patient in DENALI-1, its allogeneic A2B395 study.
- **2026** — A2 Bio reported further regulatory and clinical milestones across its logic-gated cell-therapy pipeline.

## Achievements

- Won a 2007 Wharton Venture Award while pursuing his MBA.
- Co-founded Proxim Diagnostics and led the point-of-care diagnostics company as CEO for seven years from concept toward product realization.
- Named as a co-inventor on a U.S. patent for carbon-based electrodes with graphene modification, assigned to Proxim Diagnostics.
- Led business-development work at Mammoth Biosciences that A2 Bio describes as producing major partnerships across therapeutic and diagnostic business units.
- Brought nearly two decades of business development, product management and operations experience to A2 Biotherapeutics as chief business officer.

## Latest updates

- **2026-09** — A2 Biotherapeutics announced findings from the DENALI-1 study of A2B395, its precision CAR-T program for EGFR-expressing solid tumors.
- **2026-04** — A2 Bio received FDA Fast Track designation for A2B543, a logic-gated CAR-T program enhanced with a membrane-tethered IL-12 booster.
- **2025-06** — A2 Bio dosed the first patient in the Phase 1/2 DENALI-1 study of allogeneic A2B395.
- **2025-01** — A2 Bio closed an $80 million Series C financing to support its clinical programs and Tmod-based pipeline.

## Links

- Website: https://www.a2bio.com/member/vikram-joshi/
- LinkedIn: https://www.linkedin.com/in/vikram-joshi-bb626a19a

---

Profile page: https://yespress.io/vikram-joshi
Published by YesPress — https://yespress.io
Last updated: 2026-09-26